$SPDR S&P 500 ETF Trust(SPY)$  This thing is incredibly resilient. Despite all the bad news, it's only about 14 off its highs.

$SPDR S&P 500 ETF Trust(SPY)$  It's quite obvious the next session is shaping up to be another big green day. Not even a -1% correction today. If you're bearish, sleep with one eye open.

$Intel(INTC)$ I switched my position. I'm going long after it held up today. Looking for 132 overnight and 140 easily after that.

$Intel(INTC)$ A day trader told me earlier he was absolutely certain this would go down today. He also said I wasn't worthy to clean his toilet. Pity, because I'm actually really good at cleaning toilets. I have a master's degree in the custodial arts.

$Intel(INTC)$  Well done, everyone. We are green, and green means go.

$Advanced Micro Devices(AMD)$ $Meta Platforms, Inc.(META)$ $Intel(INTC)$  $Rum Group Inc(RUM)$ $Webull Corp(BULL)$ My net worth went up by $160K today across these five stocks, with most of the gain coming from the first three.

This is pretty notable. $Intel(INTC)$  is up more than 14% as over $54M+ in net calls have been bought. Intel is currently on track for its biggest single-day gain since April 24th.

$SPDR S&P 500 ETF Trust(SPY)$  Any sell-off early in the week looks like a buying opportunity. There should be plenty of positive headlines after the China meeting wraps up before the end of the week.

$SPDR S&P 500 ETF Trust(SPY)$  Looks like there's a major catalyst building for SPY. The market is starting to factor in midterm-related political shifts, and analysts see this as a very large catalyst for SPY.

$Intel(INTC)$ I bought in the $97-103 range and sold at $110. Now I am hoping for $105 so I can run the same setup again.

$SPDR S&P 500 ETF Trust(SPY)$ $Invesco QQQ(QQQ)$ $SPDR Dow Jones Industrial Average ETF Trust(DIA)$ Financial advisors get rich whether their advice works or not.

$Intel(INTC)$  Rate hike is priced in. Time to get those calls!

$SPDR S&P 500 ETF Trust(SPY)$  Futures are up 0.3%, and the bears who bought puts at the bottom today are coping.

$Intel(INTC)$ Bears wanted to see a signed contract between Hynix and Intel, but that's not really logical. Good news pushed the price up, and the price is what matters here. I have all the right tools. I could tell the bears how this ends, but they're smart enough to already know.

$SPDR S&P 500 ETF Trust(SPY)$  A lot of traders seem to be expecting a rough day tomorrow, and that alone has me leaning bullish.

$Intel(INTC)$ It was down 7.50% and I was actually adding to my long-term position. Let the market makers keep pushing it lower. A short-term drop doesn't matter much to me since I'm thinking longer term anyway. I've been expecting this kind of move for a couple of weeks now.

$Taiwan Semiconductor Manufacturing(TSM)$ $Intel(INTC)$ $Broadcom(AVGO)$ AI names are getting hit again on what looks like an unwarranted crisis, almost as if it was manufactured to create an entry. Total nonsense. The panic sellers and politicians are at it once more.

On the 5-minute chart, this contraction should resolve within the next couple of candles. The key levels here are the 757.55 lower 15-minute ORB, PML at 757.69, 20 SMA at 757.84, and lower daily EM at 757.92. Bulls need a break above 758. Bears need a 5-minute close below 757.55, then confirmation for a signal that $SPDR S&P 500 ETF Trust(SPY)$  could head lower. The lower wicks on the candles show price is being defended by buyers. Volume has increased, which points to positioning for the next session.

$SPDR S&P 500 ETF Trust(SPY)$ The market is down, but statistically there is a decent chance of a bounce on 9/11, since market makers tend to commemorate that day. Even around midterms, the market has usually been up.

$Lexicon Pharmaceuticals(LXRX)$ Citi webcast takeaways: execution looks disciplined, with less emphasis on hype. 1. T1D NDA for Zynquista is targeted for a Q4 submission. Exton confirmed the Steno-1 exposure hurdle was hit in late August, saying the data is done and they're preparing it to get ready to submit. DKA rate came in lower than inTandem and similar to standard of care, which meets the risk-benefit criteria FDA has laid out. 2. HCM North Star is tracking toward Q1 '27. SONATA-HCM over-enrolled past 500 patients across 130+ sites, with a broad EF range and a unique background CMI cohort. Management framed a +3-pt placebo-adjusted KCCQ delta as a commercial home run. 3. Capital discipline on pain: Pilavapadin (LX9211) won't drain cash